{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+and+ribavirin&page=3",
    "query": {
      "intervention": "Pegylated interferon and ribavirin",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 124,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+and+ribavirin&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+and+ribavirin&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T22:13:48.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00984620",
      "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon-alpha (IFN)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2009-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 6,
      "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more",
      "locations": [
        {
          "city": "Tulepo",
          "state": "Mississippi"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00984620"
    },
    {
      "nct_id": "NCT00211848",
      "title": "Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Polyenylphosphatidylcholine (PPC)",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "21 Years to 67 Years"
      },
      "enrollment_count": 207,
      "start_date": "2000-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00211848"
    },
    {
      "nct_id": "NCT00978497",
      "title": "Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ANA598",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 97,
      "start_date": "2009-09",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2017-03-31",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 20,
      "location_summary": "Anaheim, California • Los Angeles, California • San Clemente, California + 17 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Clemente",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978497"
    },
    {
      "nct_id": "NCT01329978",
      "title": "Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2011-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 44,
      "location_summary": "Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329978"
    },
    {
      "nct_id": "NCT01465516",
      "title": "Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Boceprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrowhead Regional Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 105,
      "start_date": "2011-11",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 1,
      "location_summary": "Riverside, California",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465516"
    },
    {
      "nct_id": "NCT00593151",
      "title": "Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Locteron (controlled-release interferon alpha 2b)",
          "type": "OTHER"
        },
        {
          "name": "pegylated IFNa2b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Biolex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2008-01",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-02-03",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 5,
      "location_summary": "Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Annandale",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593151"
    },
    {
      "nct_id": "NCT01273064",
      "title": "Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "CTS-1027",
          "type": "DRUG"
        },
        {
          "name": "pegylated interferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2011-01",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-11",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273064"
    },
    {
      "nct_id": "NCT00136214",
      "title": "Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "MR brain and neuropsychiatric tests",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2004-03",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00136214"
    },
    {
      "nct_id": "NCT01479868",
      "title": "A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus Genotype-1"
      ],
      "interventions": [
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 109,
      "start_date": "2011-10",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-10-29",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479868"
    },
    {
      "nct_id": "NCT00194857",
      "title": "Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia",
        "Neutropenia",
        "Hepatitis C Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "erythropoietin, GCSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": null,
      "start_date": "2002-02",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-17",
      "last_synced_at": "2026-10-11T22:13:48.887Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00194857"
    }
  ]
}